# NeuroPace Inc: overview NPCE · Nasdaq · CIK 1528287 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/npce.md) · [Financials](/companies/npce/financials.md) · [Filings](/companies/npce/filings.md) · [Insiders](/companies/npce/insiders.md) Latest reported revenue: [$22.8m](/filings/0001528287-26-000030.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001528287-26-000030). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [21.1](/filings/0001528287-25-000032.md) | [21.5 d](/filings/0001528287-26-000011.md) | [22.5](/filings/0001528287-26-000022.md) | [19.5](/filings/0001528287-26-000030.md) | [27.4](/filings/0001528287-25-000032.md) | [26.6 d](/filings/0001528287-26-000011.md) | [22.1](/filings/0001528287-26-000022.md) | [22.8](/filings/0001528287-26-000030.md) | | Gross margin | % | [73.2%](/filings/0001528287-25-000032.md) | [75.4% d](/filings/0001528287-26-000011.md) | [77.0%](/filings/0001528287-26-000022.md) | [83.1%](/filings/0001528287-26-000030.md) | [77.4%](/filings/0001528287-25-000032.md) | [77.4% d](/filings/0001528287-26-000011.md) | [81.8%](/filings/0001528287-26-000022.md) | [82.8%](/filings/0001528287-26-000030.md) | | Operating margin | % | [(20.1%)](/filings/0001528287-25-000032.md) | [(17.0%) d](/filings/0001528287-26-000011.md) | [(22.9%)](/filings/0001528287-26-000022.md) | [(42.0%)](/filings/0001528287-26-000030.md) | [(9.5%)](/filings/0001528287-25-000032.md) | [(6.6%) d](/filings/0001528287-26-000011.md) | [(25.2%)](/filings/0001528287-26-000022.md) | [(22.5%)](/filings/0001528287-26-000030.md) | | Net margin | % | [(25.9%)](/filings/0001528287-25-000032.md) | [(24.5%) d](/filings/0001528287-26-000011.md) | [(29.3%)](/filings/0001528287-26-000030.md) | [(44.4%)](/filings/0001528287-26-000030.md) | [(12.8%)](/filings/0001528287-25-000032.md) | [(10.3%) d](/filings/0001528287-26-000011.md) | [(30.3%)](/filings/0001528287-26-000030.md) | [(27.2%)](/filings/0001528287-26-000030.md) | | Diluted EPS | $ per share | [(0.19)](/filings/0001528287-25-000032.md) | not reported | [(0.21)](/filings/0001528287-26-000022.md) | [(0.26)](/filings/0001528287-26-000030.md) | [(0.11)](/filings/0001528287-25-000032.md) | not reported | [(0.20)](/filings/0001528287-26-000022.md) | [(0.18)](/filings/0001528287-26-000030.md) | | Free cash flow | $m | [(1.8) d](/filings/0001528287-25-000032.md) | [(4.8) d](/filings/0001528287-26-000011.md) | [(7.5)](/filings/0001528287-26-000022.md) | [(2.3) d](/filings/0001528287-26-000030.md) | [(2.0) d](/filings/0001528287-25-000032.md) | [0.4 d](/filings/0001528287-26-000011.md) | [(6.0)](/filings/0001528287-26-000022.md) | [(4.0) d](/filings/0001528287-26-000030.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [45.2](/filings/0001528287-23-000007.md) | [45.5](/filings/0001528287-24-000005.md) | [65.4](/filings/0001528287-25-000007.md) | [79.9](/filings/0001528287-26-000011.md) | [100.0](/filings/0001528287-26-000011.md) | | Gross margin | % | [74.0%](/filings/0001528287-23-000007.md) | [71.4%](/filings/0001528287-24-000005.md) | [73.6%](/filings/0001528287-25-000007.md) | [73.9%](/filings/0001528287-26-000011.md) | [77.2%](/filings/0001528287-26-000011.md) | | Operating margin | % | [(52.5%)](/filings/0001528287-23-000007.md) | [(89.6%)](/filings/0001528287-24-000005.md) | [(41.5%)](/filings/0001528287-25-000007.md) | [(27.1%)](/filings/0001528287-26-000011.md) | [(16.3%)](/filings/0001528287-26-000011.md) | | Net margin | % | [(79.9%)](/filings/0001528287-23-000007.md) | [(103.4%)](/filings/0001528287-24-000005.md) | [(50.4%)](/filings/0001528287-25-000007.md) | [(34.0%)](/filings/0001528287-26-000011.md) | [(21.5%)](/filings/0001528287-26-000011.md) | | Diluted EPS | $ per share | [(2.17)](/filings/0001528287-23-000007.md) | [(1.91)](/filings/0001528287-24-000005.md) | [(1.27)](/filings/0001528287-25-000007.md) | [(0.93)](/filings/0001528287-26-000011.md) | [(0.66)](/filings/0001528287-26-000011.md) | | Free cash flow | $m | [(25.0)](/filings/0001528287-23-000007.md) | [(37.5)](/filings/0001528287-24-000005.md) | [(19.9)](/filings/0001528287-25-000007.md) | [(18.3)](/filings/0001528287-26-000011.md) | [(11.3)](/filings/0001528287-26-000011.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/npce/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Polar Capital Holdings Plc](/funds/1837309.md) | 2026-06-30 | $52.4m | 3,298,104 | | Unchanged | | [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $46.3m | 2,911,122 | | Reduced −21,085 | | [First Light Asset Management, LLC](/funds/1600004.md) | 2026-06-30 | $45.5m | 2,861,167 | | Added +401,201 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $42.2m | 2,654,391 | | Added +87,552 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $39.4m | 2,477,603 | | Added +131,270 | | [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $23.9m | 1,505,125 | | Reduced −591,402 | | [Driehaus Capital Management LLC](/funds/938206.md) | 2026-06-30 | $23.0m | 1,447,391 | | Reduced −4,220 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $19.5m | 1,227,072 | | Added +103,361 | | [DEUTSCHE BANK AG\\](/funds/948046.md) | 2026-06-30 | $14.9m | 938,919 | | Added +6,829 | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $11.0m | 692,000 | | Unchanged | ## Recent filings [All 350 filings](/companies/npce/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-11 | 16:33 ET | [10-Q](/filings/0001528287-26-000030.md) | Quarterly report, period 2026-06-30 | 0001528287-26-000030 | | 2026-08-11 | 16:07 ET | [8-K](/filings/0001528287-26-000027.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001528287-26-000027 | | 2026-07-28 | 16:31 ET | [8-K](/filings/0001193125-26-321083.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-321083 | | 2026-06-08 | 16:54 ET | [8-K](/filings/0001193125-26-261965.md) | 5.07 Shareholder vote results | 0001193125-26-261965 | | 2026-05-12 | 16:45 ET | [10-Q](/filings/0001528287-26-000022.md) | Quarterly report, period 2026-03-31 | 0001528287-26-000022 | | 2026-05-12 | 16:07 ET | [8-K](/filings/0001528287-26-000019.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001528287-26-000019 | | 2026-04-21 | 16:05 ET | [DEF 14A](/filings/0001140361-26-015894.md) | Proxy statement, period 2026-06-05 | 0001140361-26-015894 | | 2026-03-03 | 16:54 ET | [10-K](/filings/0001528287-26-000011.md) | Annual report, period 2025-12-31 | 0001528287-26-000011 | | 2026-03-03 | 16:09 ET | [8-K](/filings/0001528287-26-000008.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001528287-26-000008 | | 2025-11-04 | 16:22 ET | [10-Q](/filings/0001528287-25-000032.md) | Quarterly report, period 2025-09-30 | 0001528287-25-000032 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001528287-26-000011.md), filed Mar 3, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/eed472f6-f346-4218-8269-dfeec963cda6) ## About the filer - CIK: 1528287 - Tickers: NPCE - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.